arrow
J

Joon Young Song

yonsei university health system
H指数:46
被引数:9,346

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Utilisation and barriers to health check-ups among people living with human immunodeficiency virus in South Korea: a cross-sectional survey of clinic-attending patients

韩国人类免疫缺陷病毒感染者健康体检的利用及障碍:一项针对就诊患者的横断面调查

2026-09-050
OA
Trends in cancer incidence among people with human immunodeficiency virus in South Korea: a nationwide National Health Insurance Service data-based study

韩国人类免疫缺陷病毒感染者中癌症发病率的趋势:一项基于全国国民健康保险服务数据的全国性研究

2026-05-230
OA
A One-Day Pilot Point-Prevalence Survey of Healthcare-Associated Infections in Three Korean Hospitals: Risk Factors, Clinical Burden, and Implications for Nationwide Surveillance

韩国三家医院医疗相关感染的一日试点患病率调查:危险因素、临床负担及对全国性监测的启示

2026-04-090
PRE
Characteristics of Drug Resistance Mutations in a Korean HIV/AIDS Cohort, and Risk Factors for Resistance Acquisition in ART-Experienced Patients

韩国HIV/AIDS队列中药物耐药突变特征及ART经验患者获得耐药的风险因素

2026-03-010
PRE
Establishing an Active Vaccine Safety Surveillance System Using Large Scale Databases in Korea: Lessons and Scalable Insights for Global Application

利用大规模数据库建立韩国主动疫苗安全监测系统:全球应用的启示与可扩展见解

2026-01-050
OA
Long-term Immunogenicity of the 13-valent Pneumococcal Conjugate Vaccine during Adjuvant Chemotherapy in Patients with Gastric and Colorectal Cancer: A 5-Year Follow-up of a Randomized Controlled Trial

十三价肺炎球菌结合疫苗在胃癌和结直肠癌患者辅助化疗期间的长效免疫原性:一项随机对照试验的5年随访

2026-01-010
OAAI
Safety and immunogenicity of a homologous booster dose of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: 12 months follow-up result of an open-label, non-randomised extension of a phase 1/2 trial

GBP510重组蛋白纳米颗粒疫苗(一种SARS-CoV-2疫苗)与AS03佐剂同源加强针的安全性与免疫原性:一项期1/2临床试验开放标签非随机扩展研究的12个月随访结果

2025-10-080
OAAI
Estimating the clinical and economic burden of medically attended influenza in South Korea, stratified by age and comorbidity: A five-season hospital-based surveillance data, 2014/15-2018/19

评估韩国医疗关注型流感的临床和经济负担:按年龄和合并症分层,基于五季医院监测数据(2014/15-2018/19)

2025-09-170
PRE